Single-Strand Endonucleases (Origin of Replication/SI Nuclease/Mung Bean Nuclease/M Band) M

Total Page:16

File Type:pdf, Size:1020Kb

Single-Strand Endonucleases (Origin of Replication/SI Nuclease/Mung Bean Nuclease/M Band) M Proc. Nati. Acad. Sci. USA Vol. 74, No. 7, pp. 2756-2760, July 1977 Biochemistry Release of Escherichia coli DNA from membrane complexes by single-strand endonucleases (origin of replication/SI nuclease/mung bean nuclease/M band) M. ABE*, C. BROWN*, W. G. HENDRICKSON*, D. H. BOYD*, P. CLIFFORDt, R. H. COTE*, AND M. SCHAECHTER* f * Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts 02111; and t Mathematical Institute, Oxford University, Oxford, England Communicated by Gerhard Schmidt, April 22, 1977 ABSTRACT Treatment of gently prepared lysates of Esch- Incubation of Lysate with Endonucleases. Spheroplasts erichia coli with single-strand-specific endonuclease (SI or from (0.025 ml) were added to tubes containing 0.5 ml of buffer (0.1 mung beans) results in the release of about 90% of the DNA from membranes, as determined by the M band technique. The M sodium acetate, pH 5.0/1 mM ZnSO4/0.01 M Mg acetate) released DNA has an average molecular weight of about 1.2 X with heat-denatured calf thymus DNA at 5 Ag/ml. After the 108. addition of 0.01 ml of 5% Sarkosyl (Geigy Chemical Additives Data obtained with endonuclease SI fit a mathematical Co.) and 0.2-10 units of S1 or mung bean endonuclease, the model in which substrate sites are at or near membrane at- tubes were gently rolled to mix and incubated at 450 for 10-20 tachment sites. Data obtained with pancreatic deoxyribonu- min. Shark liver nuclease treatment was for 30 min at 370, and clease or x-rays fit a model for double-strand breaks at random with sites along the DNA. Fitting data to these models, we estimate samples pancreatic deoxyribonuclease (0.01-0.1 ,ug/ml) that there are 18 ± 5 membrane attachment sites. were incubated at 00 for 5 min. The DNA remaining after SI nuclease treatment is enriched Isolation of Membrane-Associated DNA (M Band). for the region near the origin of chromosome replication. Membrane-associated DNA is defined as DNA that sediments Therefore, attachment at this region appears to be chemically with Mg Sarkosyl crystals (M bands). M bands were prepared different from that at the other sites along the DNA. as follows. Samples were transferred by carefully pouring onto 15-47% sucrose gradients containing 0.01 M MgSO4/0.01 M The chromosome of Escherichla coli appears to be attached to Tris, pH 7.6 at 40/0.1 M KCl. Preformed Mg Sarkosyl crystals the cytoplasmic membrane at 20-30 sites (1, 2). The chemical (0.1-0.2 ml), obtained by mixing two parts 0.1 M Mg acetate nature of DNA attachment' to membranes is not known; In an and one part 5% Sarkosyl, were added (without mixing) to the attempt to study the chemical properties of this interaction we sample layer of each gradient. After 15 min, gradients were took as a point of departure the finding that exogenous dena- centrifuged in a Beckman SW 41 rotor at 15,000 rpm for 20-25 tured DNA sticks to membranes under conditions where native min at 4°. Tube contents were separated into a top fraction DNA does not (2, 3). This suggested to us a study of the effect containing all material above the crystal band, and an M-band of treating cell lysates with the single-strand-specific nucleases. fraction containing the crystals themselves. These fractions were We found that such nucleases from Aspergillus oryzae or mung treated with an equal volume of 10% trichloroacetic acid for bean remove DNA from the membrane in a mode that is con- 30 min on ice, filtered through GF/A filters, and washed with sistent with action of the enzymes at or near the membrane- 5% trichloroacetic acid followed by 1% acetic-acid or 95% attachment sites. These results are different from those obtained ethanol before drying and measuring radioactivity in Liqui- by random scission along the DNA. DNA near the origin of fluor/toluene scintillation fluid. replication is not released from membranes by treatment with Sizing of DNA. Samples (0.3 ml) of the treated lysate were SI nuclease. adjusted to 0.2 M NaCl and 1% sodium dodecyl sulfate. [14C]Thymidine-labeled T4 phage were added and the mixture MATERIALS AND METHODS was incubated at 630 for 20 min. The samples were poured Preparation of Spheroplasts. Ten-milliliter cultures of E. gently onto 5-20% linear sucrose gradients containing 0.05 M coli D-10 met (obtained from R. Jayaraman) were grown at sodium phosphate at pH 6.8, 0.1 M NaCl, and 0.05 M 370 in M9 salt glucose medium containing 0.2% casamino acids. Na2EDTA, and spun at 8000 rpm for 16 hr at 200 in an SW 50.1 At 0D600 = 0.15, the culture was labeled with 50-100 ,ul of rotor. Gradients were dripped onto filters (Whatman 3MM, [methyl-3H]thymidine (New England Nuclear Corp.; 1 mCi/ presoaked with 10% trichloroacetic acid), dried, and assayed ml, 6.7 Ci/mmol), and harvested at OD600 = 0.35. Cells were for radioactivity in Liquifluor/toluene scintillation fluid. resuspended in 0.25 ml of 0.1 M Tris-HCl buffer, pH 8.1 at 40, Molecular weights (Mr) were calculated by the method of containing 0.1 M NaCl and 15% sucrose (wt/vol). To this was Freifelder (4) using SI/S2 = (Mri/Mr2?a. The T4 standard added 0.01 ml of 0.25 M Na2EDTA at pH 8.1 and 0.025 ml of was assumed to have a sedimentation coefficient of 60 S and lysozyme (three times recrystallized, Sigma) at 4 mg/ml in 0.01 a molecular weight of 1.2 X 108 (4). The molecular weight of M Tris buffer. After gentle mixing for 3 min at 40, the reaction each fraction of the gradient was determined by its relative was stopped by adding 0.01 ml of 1.0 M Mg acetate, pH 5. distance from the marker. The average number of breaks was Spheroplasts were kept on ice until use. Experiments were done calculated from the equation: with E. coli PC2 dnaC thy- (obtained from Y. Hirota) using n Mr chromosome = f X (proportion cpm in fraction). similar methods. M.. 1 Mr fraction $ To whom reprint requests should be addressed. Enzymes. 51 was obtained from Miles Laboratories or pu- 2756 Downloaded by guest on September 25, 2021 Biochemistry: Abe et al. Proc. Natl. Acad. Sci. USA 74 (1977) 2757 X 20- a~~~~~~~~ 15- 10- i Bottom 10 20 30 40 Top Fraction number 5 10 15 20 25 30 Time, min FIG. 1. Size of DNA after nuclease treatment. Lysates were in- cubated and sized as described in Materials and Methods. A portion FIG. 2. Time course of DNA release from membranes by S1 nu- of each sample was also fractionated on an M band gradient. Results clease. Incubation with nuclease and M band fractionation are de- are similar with different DNA concentrations and when T4 phage scribed in Materials and Methods. Numbers next to curves indicate DNA marker is eliminated. The extrapolated molecular weight for units of enzyme used. the untreated sample is 21 X 109. Similar curves were obtained using mung bean nuclease. 0, Sample incubated without nuclease, 5% of the DNA is in the top fraction ofthe M band gradient; 0, 2 units S1, the membrane. The size of the DNA fragments released from 63% of the DNA is in the top fraction; X, 5 units S1, 85% of the DNA the membrane is relatively constant throughout the time course, is in the top fraction. Arrow indicates position of T4 phage DNA whereas the DNA that remains in the M band decreases to this marker. size limit with increasing enzyme activity (Fig. 3, which shows two of a series of analogous experiments). rified from a-amylase (see below). Mung bean and shark liver Similar results are obtained with other single-strand-specific endonucleases were kindly provided by R. Wells and E. enzymes such as mung bean and shark liver endonucleases. The Goldberg, respectively. Electrophoretically purified pancreatic ability of these enzymes to hydrolyze RNA is apparently not deoxyribonuclease was obtained from Worthington. responsible for release of DNA from the membrane because Purification of SI Endonuclease. A modification of the pretreatment with pancreatic ribonuclease has no effect on the procedure of Vogt (5) was used to purify SI endonuclease from amount of DNA in the M band either with or without SI a-amylase (crude, type IV-A from Aspergillus oryzae) obtained treatment. In a double-label experiment (not shown) it was from Sigma. Purification steps included heat treatment, two found that when the proportion of DNA released from the (NH4)2S04 precipitations, dialysis, DEAE-cellulose chroma- membrane has reached a plateau, the enzyme is fully active tography, and Sephadex G-100 gel filtration. A2j0 and nuclease against newly added lysate and that when a second plateau is activity (using either native or denatured DNA as substrate) reached, both the original and the newly added DNA approach were monitored across the column fractions. the same size limit. The incubation conditions do not reduce Assay of Single-Strand Endonuclease Activity. One or two the activity of Si on single-stranded calf thymus DNA. Release microliters of each fraction was assayed for solubilization of of DNA from the membrane by SI is inhibited strongly by the single- or double-stranded calf thymus DNA by the procedure addition of single-stranded DNA to the lysate but only slightly of Vogt (5). One unit of nuclease activity is the amount of en- by the addition of double-stranded DNA (Fig.
Recommended publications
  • Cloud-Clone 16-17
    Cloud-Clone - 2016-17 Catalog Description Pack Size Supplier Rupee(RS) ACB028Hu CLIA Kit for Anti-Albumin Antibody (AAA) 96T Cloud-Clone 74750 AEA044Hu ELISA Kit for Anti-Growth Hormone Antibody (Anti-GHAb) 96T Cloud-Clone 74750 AEA255Hu ELISA Kit for Anti-Apolipoprotein Antibodies (AAHA) 96T Cloud-Clone 74750 AEA417Hu ELISA Kit for Anti-Proteolipid Protein 1, Myelin Antibody (Anti-PLP1) 96T Cloud-Clone 74750 AEA421Hu ELISA Kit for Anti-Myelin Oligodendrocyte Glycoprotein Antibody (Anti- 96T Cloud-Clone 74750 MOG) AEA465Hu ELISA Kit for Anti-Sperm Antibody (AsAb) 96T Cloud-Clone 74750 AEA539Hu ELISA Kit for Anti-Myelin Basic Protein Antibody (Anti-MBP) 96T Cloud-Clone 71250 AEA546Hu ELISA Kit for Anti-IgA Antibody 96T Cloud-Clone 71250 AEA601Hu ELISA Kit for Anti-Myeloperoxidase Antibody (Anti-MPO) 96T Cloud-Clone 71250 AEA747Hu ELISA Kit for Anti-Complement 1q Antibody (Anti-C1q) 96T Cloud-Clone 74750 AEA821Hu ELISA Kit for Anti-C Reactive Protein Antibody (Anti-CRP) 96T Cloud-Clone 74750 AEA895Hu ELISA Kit for Anti-Insulin Receptor Antibody (AIRA) 96T Cloud-Clone 74750 AEB028Hu ELISA Kit for Anti-Albumin Antibody (AAA) 96T Cloud-Clone 71250 AEB264Hu ELISA Kit for Insulin Autoantibody (IAA) 96T Cloud-Clone 74750 AEB480Hu ELISA Kit for Anti-Mannose Binding Lectin Antibody (Anti-MBL) 96T Cloud-Clone 88575 AED245Hu ELISA Kit for Anti-Glutamic Acid Decarboxylase Antibodies (Anti-GAD) 96T Cloud-Clone 71250 AEK505Hu ELISA Kit for Anti-Heparin/Platelet Factor 4 Antibodies (Anti-HPF4) 96T Cloud-Clone 71250 CCA005Hu CLIA Kit for Angiotensin II
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0058468 A1 Mickeown (43) Pub
    US 20120058468A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0058468 A1 MickeoWn (43) Pub. Date: Mar. 8, 2012 (54) ADAPTORS FOR NUCLECACID Related U.S. Application Data CONSTRUCTS IN TRANSMEMBRANE (60) Provisional application No. 61/148.737, filed on Jan. SEQUENCING 30, 2009. Publication Classification (75) Inventor: Brian Mckeown, Oxon (GB) (51) Int. Cl. CI2O I/68 (2006.01) (73) Assignee: OXFORD NANOPORE C7H 2L/00 (2006.01) TECHNOLGIES LIMITED, (52) U.S. Cl. ......................................... 435/6.1:536/23.1 Oxford (GB) (57) ABSTRACT (21) Appl. No.: 13/147,159 The invention relates to adaptors for sequencing nucleic acids. The adaptors may be used to generate single stranded constructs of nucleic acid for sequencing purposes. Such (22) PCT Fled: Jan. 29, 2010 constructs may contain both strands from a double stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) (86) PCT NO.: PCT/GB1O/OO160 template. The invention also relates to the constructs gener ated using the adaptors, methods of making the adaptors and S371 (c)(1), constructs, as well as methods of sequencing double stranded (2), (4) Date: Nov. 15, 2011 nucleic acids. Patent Application Publication Mar. 8, 2012 Sheet 1 of 4 US 2012/0058468 A1 Figure 5' 3 Figure 2 Figare 3 Patent Application Publication Mar. 8, 2012 Sheet 2 of 4 US 2012/0058468 A1 Figure 4 End repair Acid adapters ligate adapters Patent Application Publication Mar. 8, 2012 Sheet 3 of 4 US 2012/0058468 A1 Figure 5 Wash away type ifype foducts irrirrosilise Type| capture WashRE products away unbcure Pace É: Wash away unbound rag terts Free told fasgirre?ts aid raiser to festible Figure 6 Beatre Patent Application Publication Mar.
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • Enzyme-Pore Constructs
    (19) TZZ Z_T (11) EP 2 682 460 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.01.2014 Bulletin 2014/02 C12N 9/12 (2006.01) C12N 9/22 (2006.01) C12N 9/52 (2006.01) C12Q 1/68 (2006.01) (21) Application number: 13187149.3 (22) Date of filing: 06.07.2009 (84) Designated Contracting States: • Cheley, Stephen AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Oxford HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL Oxfordshire OX4 4GA (GB) PT RO SE SI SK SM TR •McKeown,Brian Oxford (30) Priority: 07.07.2008 US 78695 P Oxfordshire OX4 4GA (GB) • White, James (62) Document number(s) of the earlier application(s) in Oxford accordance with Art. 76 EPC: Oxfordshire OX4 4GA (GB) 09784644.8 / 2 307 540 • Clarke, James Oxford (71) Applicant: Oxford Nanopore Technologies Oxfordshire OX4 4GA (GB) Limited Oxford Science Park (74) Representative: Chapman, Lee Phillip Oxford J A Kemp OX4 4GA (GB) 14 South Square Gray’s Inn (72) Inventors: London WC1R 5JJ (GB) • Jayasinghe, Lakmal Oxford Remarks: Oxfordshire OX4 4GA (GB) This application was filed on 02-10-2013 as a •Bayley,Hagan divisional application to the application mentioned Oxford under INID code 62. Oxfordshire OX4 4GA (GB) (54) Enzyme-pore constructs (57) The invention relates to constructs comprising a transmembrane protein pore subunit and a nucleic acid handling enzyme. The pore subunit is covalently at- tached to the enzyme such that both the subunit and enzyme retain their activity.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur Et Al
    US 2012026.6329A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur et al. (43) Pub. Date: Oct. 18, 2012 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/10 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/24 (2006.01) CI2N 9/02 (2006.01) (75) Inventors: Eric J. Mathur, Carlsbad, CA CI2N 9/06 (2006.01) (US); Cathy Chang, San Marcos, CI2P 2L/02 (2006.01) CA (US) CI2O I/04 (2006.01) CI2N 9/96 (2006.01) (73) Assignee: BP Corporation North America CI2N 5/82 (2006.01) Inc., Houston, TX (US) CI2N 15/53 (2006.01) CI2N IS/54 (2006.01) CI2N 15/57 2006.O1 (22) Filed: Feb. 20, 2012 CI2N IS/60 308: Related U.S. Application Data EN f :08: (62) Division of application No. 1 1/817,403, filed on May AOIH 5/00 (2006.01) 7, 2008, now Pat. No. 8,119,385, filed as application AOIH 5/10 (2006.01) No. PCT/US2006/007642 on Mar. 3, 2006. C07K I4/00 (2006.01) CI2N IS/II (2006.01) (60) Provisional application No. 60/658,984, filed on Mar. AOIH I/06 (2006.01) 4, 2005. CI2N 15/63 (2006.01) Publication Classification (52) U.S. Cl. ................... 800/293; 435/320.1; 435/252.3: 435/325; 435/254.11: 435/254.2:435/348; (51) Int. Cl. 435/419; 435/195; 435/196; 435/198: 435/233; CI2N 15/52 (2006.01) 435/201:435/232; 435/208; 435/227; 435/193; CI2N 15/85 (2006.01) 435/200; 435/189: 435/191: 435/69.1; 435/34; CI2N 5/86 (2006.01) 435/188:536/23.2; 435/468; 800/298; 800/320; CI2N 15/867 (2006.01) 800/317.2: 800/317.4: 800/320.3: 800/306; CI2N 5/864 (2006.01) 800/312 800/320.2: 800/317.3; 800/322; CI2N 5/8 (2006.01) 800/320.1; 530/350, 536/23.1: 800/278; 800/294 CI2N I/2 (2006.01) CI2N 5/10 (2006.01) (57) ABSTRACT CI2N L/15 (2006.01) CI2N I/19 (2006.01) The invention provides polypeptides, including enzymes, CI2N 9/14 (2006.01) structural proteins and binding proteins, polynucleotides CI2N 9/16 (2006.01) encoding these polypeptides, and methods of making and CI2N 9/20 (2006.01) using these polynucleotides and polypeptides.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur Et Al
    US 20150240226A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0240226A1 Mathur et al. (43) Pub. Date: Aug. 27, 2015 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/16 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/02 (2006.01) CI2N 9/78 (2006.01) (71) Applicant: BP Corporation North America Inc., CI2N 9/12 (2006.01) Naperville, IL (US) CI2N 9/24 (2006.01) CI2O 1/02 (2006.01) (72) Inventors: Eric J. Mathur, San Diego, CA (US); CI2N 9/42 (2006.01) Cathy Chang, San Marcos, CA (US) (52) U.S. Cl. CPC. CI2N 9/88 (2013.01); C12O 1/02 (2013.01); (21) Appl. No.: 14/630,006 CI2O I/04 (2013.01): CI2N 9/80 (2013.01); CI2N 9/241.1 (2013.01); C12N 9/0065 (22) Filed: Feb. 24, 2015 (2013.01); C12N 9/2437 (2013.01); C12N 9/14 Related U.S. Application Data (2013.01); C12N 9/16 (2013.01); C12N 9/0061 (2013.01); C12N 9/78 (2013.01); C12N 9/0071 (62) Division of application No. 13/400,365, filed on Feb. (2013.01); C12N 9/1241 (2013.01): CI2N 20, 2012, now Pat. No. 8,962,800, which is a division 9/2482 (2013.01); C07K 2/00 (2013.01); C12Y of application No. 1 1/817,403, filed on May 7, 2008, 305/01004 (2013.01); C12Y 1 1 1/01016 now Pat. No. 8,119,385, filed as application No. PCT/ (2013.01); C12Y302/01004 (2013.01); C12Y US2006/007642 on Mar. 3, 2006.
    [Show full text]
  • Supplementary Material (ESI) for Natural Product Reports
    Electronic Supplementary Material (ESI) for Natural Product Reports. This journal is © The Royal Society of Chemistry 2014 Supplement to the paper of Alexey A. Lagunin, Rajesh K. Goel, Dinesh Y. Gawande, Priynka Pahwa, Tatyana A. Gloriozova, Alexander V. Dmitriev, Sergey M. Ivanov, Anastassia V. Rudik, Varvara I. Konova, Pavel V. Pogodin, Dmitry S. Druzhilovsky and Vladimir V. Poroikov “Chemo- and bioinformatics resources for in silico drug discovery from medicinal plants beyond their traditional use: a critical review” Contents PASS (Prediction of Activity Spectra for Substances) Approach S-1 Table S1. The lists of 122 known therapeutic effects for 50 analyzed medicinal plants with accuracy of PASS prediction calculated by a leave-one-out cross-validation procedure during the training and number of active compounds in PASS training set S-6 Table S2. The lists of 3,345 mechanisms of action that were predicted by PASS and were used in this study with accuracy of PASS prediction calculated by a leave-one-out cross-validation procedure during the training and number of active compounds in PASS training set S-9 Table S3. Comparison of direct PASS prediction results of known effects for phytoconstituents of 50 TIM plants with prediction of known effects through “mechanism-effect” and “target-pathway- effect” relationships from PharmaExpert S-79 S-1 PASS (Prediction of Activity Spectra for Substances) Approach PASS provides simultaneous predictions of many types of biological activity (activity spectrum) based on the structure of drug-like compounds. The approach used in PASS is based on the suggestion that biological activity of any drug-like compound is a function of its structure.
    [Show full text]
  • Springer Handbook of Enzymes
    Dietmar Schomburg Ida Schomburg (Eds.) Springer Handbook of Enzymes Alphabetical Name Index 1 23 © Springer-Verlag Berlin Heidelberg New York 2010 This work is subject to copyright. All rights reserved, whether in whole or part of the material con- cerned, specifically the right of translation, printing and reprinting, reproduction and storage in data- bases. The publisher cannot assume any legal responsibility for given data. Commercial distribution is only permitted with the publishers written consent. Springer Handbook of Enzymes, Vols. 1–39 + Supplements 1–7, Name Index 2.4.1.60 abequosyltransferase, Vol. 31, p. 468 2.7.1.157 N-acetylgalactosamine kinase, Vol. S2, p. 268 4.2.3.18 abietadiene synthase, Vol. S7,p.276 3.1.6.12 N-acetylgalactosamine-4-sulfatase, Vol. 11, p. 300 1.14.13.93 (+)-abscisic acid 8’-hydroxylase, Vol. S1, p. 602 3.1.6.4 N-acetylgalactosamine-6-sulfatase, Vol. 11, p. 267 1.2.3.14 abscisic-aldehyde oxidase, Vol. S1, p. 176 3.2.1.49 a-N-acetylgalactosaminidase, Vol. 13,p.10 1.2.1.10 acetaldehyde dehydrogenase (acetylating), Vol. 20, 3.2.1.53 b-N-acetylgalactosaminidase, Vol. 13,p.91 p. 115 2.4.99.3 a-N-acetylgalactosaminide a-2,6-sialyltransferase, 3.5.1.63 4-acetamidobutyrate deacetylase, Vol. 14,p.528 Vol. 33,p.335 3.5.1.51 4-acetamidobutyryl-CoA deacetylase, Vol. 14, 2.4.1.147 acetylgalactosaminyl-O-glycosyl-glycoprotein b- p. 482 1,3-N-acetylglucosaminyltransferase, Vol. 32, 3.5.1.29 2-(acetamidomethylene)succinate hydrolase, p. 287 Vol.
    [Show full text]
  • CLOUD-CLONE 製品リスト Shigematsu Co.,LTD
    CLOUD-CLONE 製品リスト Shigematsu Co.,LTD. Product No. Name Format CEA544Hu ELISA Kit for Immunoglobulin G (IgG) 96-well strip plate CEB409Hu ELISA Kit for Hemoglobin (HB) 96-well strip plate CEB028Ra ELISA Kit for Albumin (ALB) 96-well strip plate SEB409Mu ELISA Kit for Hemoglobin (HB) 96-well strip plate CEA544Gu ELISA Kit for Immunoglobulin G (IgG) 96-well strip plate SEB409Rb ELISA Kit for Hemoglobin (HB) 96-well strip plate CEB028Rb ELISA Kit for Albumin (ALB) 96-well strip plate SEB409Ra ELISA Kit for Hemoglobin (HB) 96-well strip plate CEB028Gu ELISA Kit for Albumin (ALB) 96-well strip plate HEA544Hu High Sensitive ELISA Kit for Immunoglobulin G (IgG) 96-well strip plate CEA544Mu ELISA Kit for Immunoglobulin G (IgG) 96-well strip plate CEB028Mu ELISA Kit for Albumin (ALB) 96-well strip plate CEC036Mu ELISA Kit for Transferrin (TRF) 96-well strip plate CEA544Ga ELISA Kit for Immunoglobulin G (IgG) 96-well strip plate CEA544Ra ELISA Kit for Immunoglobulin G (IgG) 96-well strip plate CEA544Rb ELISA Kit for Immunoglobulin G (IgG) 96-well strip plate SEB409Gu ELISA Kit for Hemoglobin (HB) 96-well strip plate SEA448Hu ELISA Kit for Insulin (INS) 96-well strip plate SEA480Hu ELISA Kit for Myoglobin (MYO) 96-well strip plate SEA518Hu ELISA Kit for Ferritin (FE) 96-well strip plate SEC036Ca ELISA Kit for Transferrin (TRF) 96-well strip plate CEB028Hu ELISA Kit for Albumin (ALB) 96-well strip plate CEB028Ca ELISA Kit for Albumin (ALB) 96-well strip plate SEB409Eq ELISA Kit for Hemoglobin (HB) 96-well strip plate SEA049Hu ELISA Kit for Interferon
    [Show full text]
  • WO 2010/086622 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENTCOOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 5 August 2010 (05.08.2010) WO 2010/086622 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/GB20 10/000 160 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 29 January 2010 (29.01 .2010) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/148,737 30 January 2009 (30.01 .2009) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): OX¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, FORD NANOPORE TECHNOLOGIES LIMITED ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, [GB/GB]; Edmund Cartwright House, 4 Robert Robinson TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Avenue, Oxford Science Park, Oxford OX4 4GA (GB).
    [Show full text]
  • Highly Sensitive Fluorescent Methods for the Detection of Enzymes and the Determination of Their Activity by Means of Specific Hydrolases
    Sigrun Henkenjohann DISSERTATION Highly Sensitive Fluorescent Methods for the Detection of Enzymes and the Determination of their Activity by Means of Specific Hydrolases APPLIED LASER PHYSICS AND LASER SPECTROSCOPY FACULTY OF PHYSICS - BIELEFELD UNIVERSITY Printed on non-aging, wood- and acid-free paper according to DIN-ISO 9706. Gedruckt auf alterungsbeständigem, holz- und säurefreiem Papier gemäß DIN-ISO 9706. Dissertation Highly Sensitive Fluorescent Methods for the Detection of Enzymes and the Determination of their Activity by Means of Specific Hydrolases Sigrun Henkenjohann December 8th 2009 Applied Laser Physics & Laser Spectroscopy Department of Physics Bielefeld University Reviewer: Markus Sauer Andreas Hütten Zusammenfassung In sehr vielen biologischen und medizinischen Prozessen nehmen Enzyme ei- ne wichtige Schlüsselfunktion ein [1–27], auf die Einfluss genommen werden kann, wenn die betreffenden Enzyme gesteuert werden können. Dies jedoch verlangt nach einem genauen Verständnis der enzymatischen Vorgänge, wel- ches mithilfe der Fluoreszensmikroskopie verbessert werden kann. In dieser Arbeit werden zwei unterschiedliche Ansätze zur fluoreszenten Enzymologie für die Carboxypeptidase A und vier verschiedene Nukleasen vorgestellt und ausgewertet. Der erste dieser Ansätze nutzt fluoreszierende Enzymsubstrate, die sich die intrinsischen elektronspendenden Eigenschaften der natürlich vorkommenden Aminosäure Tryptophan und der Nukleinsäure Guanosin zu Nutze machen [28–34]. Verschiedene Peptidsubstrate für die Untersuchung der Carboxypeptidase A, und zwei Gruppen von sogenannten ’smart probes’ für die Untersuchung der DNaseI, DNaseII, S1-Nuklease und der DNaseX werden vorgestellt, cha- rakterisiert und im weiteren Verlauf für die Analyse spezifischer Enzymeigen- schaften angewandt. Schon kleine Unterschiede in Amino- und Nukleinsäu- resequenzen dieser Substrate führen zu großen Veränderungen der relativen Quantenausbeuten, des Hitzeverhaltens der Substrate und des Enzymumsat- zes.
    [Show full text]